Loading insider details...
Beta
Latest Form 4 (Jun 26, 2026): Grant/Award of 30,000 SPRY shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 26, 2026 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 30,000 | n/a |
| Jun 27, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 30,000 | n/a |
| May 30, 2025 | Passage BIO, Inc. (PASG) | Grant/Award | 201,857 | n/a |
| Sep 4, 2024 | SpringWorks Therapeutics, Inc. (SWTX) | Sale | 32,400 | $1.30M |
| Jun 24, 2024 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 40,000 | n/a |
| Jun 5, 2024 | SpringWorks Therapeutics, Inc. (SWTX) | Sale | 33,240 | $1.31M |
| May 23, 2024 | Passage BIO, Inc. (PASG) | Grant/Award | 47,693 | n/a |
| Jan 8, 2024 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/Award | 88,000 | n/a |
| Jun 29, 2023 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 40,000 | n/a |
| May 26, 2023 | Passage BIO, Inc. (PASG) | Grant/Award | 24,000 | n/a |